Pricing Log in Create free account
Friday 6 November 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.

Revenue
+11.9%
EPS
−39.2%
Free cash flow
−52.1%

Quarter to September 2026, against a year earlier

547.43 4.93 +0.91%
Market cap
$137.5B
P/E
34.6×
Fwd P/E
33.2×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Vertex Pharmaceuticals Incorporated 8-K filed Feb 12, 2026

Period ended Feb 12, 2026 · Filed · accepted 4:04 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release